Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Discussing suicidality with depressed patients: an observational study in Dutch sentinel general practices.

Elzinga E, Gilissen R, Donker GA, Beekman ATF, de Beurs DP.

BMJ Open. 2019 Apr 24;9(4):e027624. doi: 10.1136/bmjopen-2018-027624.

2.

Feasibility and impact of data-driven learning within the suicide prevention action network of thirteen specialist mental healthcare institutions (SUPRANET Care) in the Netherlands: a study protocol.

Setkowski K, Mokkenstorm J, van Balkom AJ, Franx G, Verbeek-van Noord I, Dongelmans DA, Eikelenboom M, Gilissen R.

BMJ Open. 2018 Aug 20;8(8):e024398. doi: 10.1136/bmjopen-2018-024398.

3.

[Issues in emergency care for people who attempted suicide].

Mérelle SYM, Boerema I, van der Linden MC, Gilissen R.

Ned Tijdschr Geneeskd. 2018 Jul 2;162. pii: D2463. Dutch.

PMID:
30040297
4.

Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.

Lu T, Schubert C, Cummings MD, Bignan G, Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, Alexander R, Grasberger B, De Breucker S, Esser N, Fraiponts E, Gilissen R, Janssens B, Peeters D, Van Nuffel L, Vermeulen P, Bischoff J, Meerpoel L.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2159-2164. doi: 10.1016/j.bmcl.2018.05.014. Epub 2018 May 8.

PMID:
29779975
5.

Suicide prevention gatekeeper training in the Netherlands improves gatekeepers' knowledge of suicide prevention and their confidence to discuss suicidality, an observational study.

Terpstra S, Beekman A, Abbing J, Jaken S, Steendam M, Gilissen R.

BMC Public Health. 2018 May 18;18(1):637. doi: 10.1186/s12889-018-5512-8.

6.

Suicide Prevention Guideline Implementation in Specialist Mental Healthcare Institutions in The Netherlands.

Mokkenstorm J, Franx G, Gilissen R, Kerkhof A, Smit JH.

Int J Environ Res Public Health. 2018 May 3;15(5). pii: E910. doi: 10.3390/ijerph15050910.

7.

Characteristics Associated with Non-Disclosure of Suicidal Ideation in Adults.

Mérelle S, Foppen E, Gilissen R, Mokkenstorm J, Cluitmans R, Van Ballegooijen W.

Int J Environ Res Public Health. 2018 May 9;15(5). pii: E943. doi: 10.3390/ijerph15050943.

8.

Improving Suicide Prevention in Dutch Regions by Creating Local Suicide Prevention Action Networks (SUPRANET): A Study Protocol.

Gilissen R, De Beurs D, Mokkenstorm J, Mérelle S, Donker G, Terpstra S, Derijck C; The Supranet Suicide Prevention Action Network Research Group, Franx G.

Int J Environ Res Public Health. 2017 Mar 28;14(4). pii: E349. doi: 10.3390/ijerph14040349.

9.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV.

Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24.

10.

Evaluation of the 113Online Suicide Prevention Crisis Chat Service: Outcomes, Helper Behaviors and Comparison to Telephone Hotlines.

Mokkenstorm JK, Eikelenboom M, Huisman A, Wiebenga J, Gilissen R, Kerkhof AJFM, Smit JH.

Suicide Life Threat Behav. 2017 Jun;47(3):282-296. doi: 10.1111/sltb.12286. Epub 2016 Aug 19.

PMID:
27539122
11.

A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.

Zhou X, Huntjens D, Gilissen R.

CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):650-9. doi: 10.1002/psp4.12035. Epub 2015 Oct 9.

12.

Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.

de Witte WE, Wong YC, Nederpelt I, Heitman LH, Danhof M, van der Graaf PH, Gilissen RA, de Lange EC.

Expert Opin Drug Discov. 2016;11(1):45-63. doi: 10.1517/17460441.2016.1100163. Epub 2015 Oct 20. Review.

PMID:
26484747
13.

Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.

Johnson CN, Adelinet C, Berdini V, Beke L, Bonnet P, Brehmer D, Calo F, Coyle JE, Day PJ, Frederickson M, Freyne EJ, Gilissen RA, Hamlett CC, Howard S, Meerpoel L, Mevellec L, McMenamin R, Pasquier E, Patel S, Rees DC, Linders JT.

ACS Med Chem Lett. 2014 May 23;6(1):31-6. doi: 10.1021/ml5001273. eCollection 2015 Jan 8.

14.

Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.

Johnson CN, Berdini V, Beke L, Bonnet P, Brehmer D, Coyle JE, Day PJ, Frederickson M, Freyne EJ, Gilissen RA, Hamlett CC, Howard S, Meerpoel L, McMenamin R, Patel S, Rees DC, Sharff A, Sommen F, Wu T, Linders JT.

ACS Med Chem Lett. 2014 May 23;6(1):25-30. doi: 10.1021/ml5001245. eCollection 2015 Jan 8.

15.

Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria.

Balemans W, Vranckx L, Lounis N, Pop O, Guillemont J, Vergauwen K, Mol S, Gilissen R, Motte M, Lançois D, De Bolle M, Bonroy K, Lill H, Andries K, Bald D, Koul A.

Antimicrob Agents Chemother. 2012 Aug;56(8):4131-9. doi: 10.1128/AAC.00273-12. Epub 2012 May 21.

16.

Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.

Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K.

Antimicrob Agents Chemother. 2012 Mar;56(3):1444-51. doi: 10.1128/AAC.00720-11. Epub 2011 Dec 12.

17.

Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.

Van den Bergh A, Sinha V, Gilissen R, Straetemans R, Wuyts K, Morrison D, Bijnens L, Mackie C.

Clin Pharmacokinet. 2011 Aug;50(8):505-17. doi: 10.2165/11587230-000000000-00000.

PMID:
21740074
18.

Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.

Sinha VK, Vaarties K, De Buck SS, Fenu LA, Nijsen M, Gilissen RA, Sanderson W, Van Uytsel K, Hoeben E, Van Peer A, Mackie CE, Smit JW.

Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000.

PMID:
21456631
19.

Essentiality of FASII pathway for Staphylococcus aureus.

Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A.

Nature. 2010 Jan 21;463(7279):E3; discussion E4. doi: 10.1038/nature08667.

PMID:
20090698
20.

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30.

PMID:
19906529
21.

Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay.

Fenu LA, Teisman A, De Buck SS, Sinha VK, Gilissen RA, Nijsen MJ, Mackie CE, Sanderson WE.

J Comput Aided Mol Des. 2009 Dec;23(12):883-95. doi: 10.1007/s10822-009-9306-z. Epub 2009 Nov 5.

PMID:
19890608
22.

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P.

Clin Cancer Res. 2009 Nov 15;15(22):6841-51. doi: 10.1158/1078-0432.CCR-09-0547. Epub 2009 Oct 27.

23.

Electrodermal reactivity during the Trier Social Stress Test for children: interaction between the serotonin transporter polymorphism and children's attachment representation.

Gilissen R, Bakermans-Kranenburg MJ, van Ijzendoorn MH, Linting M.

Dev Psychobiol. 2008 Sep;50(6):615-25. doi: 10.1002/dev.20314.

PMID:
18683185
24.

Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.

Buntinx M, Hermans B, Goossens J, Moechars D, Gilissen RA, Doyon J, Boeckx S, Coesemans E, Van Lommen G, Van Wauwe JP.

J Pharmacol Exp Ther. 2008 Oct;327(1):1-9. doi: 10.1124/jpet.108.140723. Epub 2008 Jul 3.

PMID:
18599682
25.

Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.

Doyon J, Coesemans E, Boeckx S, Buntinx M, Hermans B, Van Wauwe JP, Gilissen RA, De Groot AH, Corens D, Van Lommen G.

ChemMedChem. 2008 Apr;3(4):660-9. doi: 10.1002/cmdc.200700276.

PMID:
18188859
26.

Predicting oral clearance in humans: how close can we get with allometry?

Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE.

Clin Pharmacokinet. 2008;47(1):35-45.

PMID:
18076217
27.

Parent-child relationship, temperament, and physiological reactions to fear-inducing film clips: further evidence for differential susceptibility.

Gilissen R, Bakermans-Kranenburg MJ, van IJzendoorn MH, van der Veer R.

J Exp Child Psychol. 2008 Mar;99(3):182-95. Epub 2007 Aug 6.

PMID:
17681350
28.

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.

De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA.

Drug Metab Dispos. 2007 Oct;35(10):1766-80. Epub 2007 Jul 9.

PMID:
17620347
29.

A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes.

Saenen JB, Paulussen AD, Jongbloed RJ, Marcelis CL, Gilissen RA, Aerssens J, Snyders DJ, Raes AL.

J Mol Cell Cardiol. 2007 Jul;43(1):63-72. Epub 2007 May 4.

PMID:
17531263
30.

Physiological reactions of preschoolers to fear-inducing film clips: effects of temperamental fearfulness and quality of the parent-child relationship.

Gilissen R, Koolstra CM, van Ijzendoorn MH, Bakermans-Kranenburg MJ, van der Veer R.

Dev Psychobiol. 2007 Mar;49(2):187-95.

PMID:
17299791
31.
32.

Chiral capillary electrophoretic analysis of verapamil metabolism by cytochrome P450 3A4.

Ha PT, Sluyts I, Van Dyck S, Zhang J, Gilissen RA, Hoogmartens J, VanSchepdael A.

J Chromatogr A. 2006 Jul 7;1120(1-2):94-101. Epub 2005 Dec 27.

PMID:
16376901
33.

HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.

Paulussen AD, Raes A, Jongbloed RJ, Gilissen RA, Wilde AA, Snyders DJ, Smeets HJ, Aerssens J.

Cardiovasc Res. 2005 Aug 15;67(3):467-75.

PMID:
15958262
34.
35.

The use of liquid chromatography-atmospheric pressure chemical ionization mass spectrometry to explore the in vitro metabolism of cyanoalkyl piperidine derivatives.

Kantharaj E, Ehmer PB, De Wagter K, Tuytelaars A, Proost PE, Mackie C, Gilissen RA.

Biomed Chromatogr. 2005 Apr;19(3):245-9.

PMID:
15627277
36.

Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes.

Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G, Meuldermans W.

Biochem Pharmacol. 2004 Feb 1;67(3):427-37.

PMID:
15037195
37.

Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.

Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J.

J Mol Med (Berl). 2004 Mar;82(3):182-8. Epub 2004 Feb 4.

PMID:
14760488
38.

Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry.

Kantharaj E, Tuytelaars A, Proost PE, Ongel Z, Van Assouw HP, Gilissen RA.

Rapid Commun Mass Spectrom. 2003;17(23):2661-8.

PMID:
14648905
39.

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK.

Biochem Pharmacol. 2002 Dec 1;64(11):1579-89.

PMID:
12429347
40.

Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced risk of colorectal cancer.

Bamber DE, Fryer AA, Strange RC, Elder JB, Deakin M, Rajagopal R, Fawole A, Gilissen RA, Campbell FC, Coughtrie MW.

Pharmacogenetics. 2001 Nov;11(8):679-85.

PMID:
11692076
41.

The human genome: an introduction.

Aerssens J, Armstrong M, Gilissen R, Cohen N.

Oncologist. 2001;6(1):100-9. Review. No abstract available.

42.

Identification of UDP-glucuronosyltransferases involved in the human hepatic metabolism of GV150526, a novel glycine antagonist.

Gilissen RA, Barnaby RJ, Kajbaf M.

Drug Metabol Drug Interact. 2000;16(3):173-89.

PMID:
11116752
43.

Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: in vitro-in vivo correlations.

Gilissen RA, Ferrari L, Barnaby RJ, Kajbaf M.

Xenobiotica. 2000 Sep;30(9):843-56.

PMID:
11055263
44.

Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations.

Coughtrie MW, Gilissen RA, Shek B, Strange RC, Fryer AA, Jones PW, Bamber DE.

Biochem J. 1999 Jan 1;337 ( Pt 1):45-9.

45.

Sulphation of N-hydroxy-4-aminobiphenyl and N-hydroxy-4-acetylaminobiphenyl by human foetal and neonatal sulphotransferase.

Gilissen RA, Hume R, Meerman JH, Coughtrie MW.

Biochem Pharmacol. 1994 Aug 17;48(4):837-40.

PMID:
8080456
46.
47.

Sulfation of aromatic hydroxamic acids and hydroxylamines by multiple forms of human liver sulfotransferases.

Gilissen RA, Bamforth KJ, Stavenuiter JF, Coughtrie MW, Meerman JH.

Carcinogenesis. 1994 Jan;15(1):39-45.

PMID:
8293546
48.

Sulfation of hydroxylamines and hydroxamic acids in liver cytosol from male and female rats and purified aryl sulfotransferase IV.

Gilissen RA, Ringer DP, Stavenuiter HJ, Mulder GJ, Meerman JH.

Carcinogenesis. 1992 Oct;13(10):1699-703.

PMID:
1423828
49.

Immobilization of solubilized UDP-glucuronosyltransferase from rat liver microsomes to Sepharose 4B.

Gilissen RA, Meerman JH, Mulder GJ.

Biochem Pharmacol. 1992 Jun 23;43(12):2661-3.

PMID:
1632822

Supplemental Content

Loading ...
Support Center